SUMMARY In 11 children aged between 2 and 17 years with (nonsalt-losing) congenital adrenal hyperplasia (21-hydroxylase deficiency) blood was drawn at 90-minute intervals during a 24-hour period and levels of 17-hydroxyprogesterone, testosterone, and cortisol were measured. Levels of 1 7-ketosteroids and pregnanetriol were measured too in 24-hour urine samples. These measurements were taken under different regimens of treatment and after interruption of treatment. Cortisol levels rose and fell rapidly after administered corticosteroid, and reached unphysiologically high levels. Testosterone levels showed pronounced variations but stayed in the normal range for most of the time even in untreated patients; thus testosterone provides a poor control parameter. Levels of 1 7-hydroxyprogesterone showed extreme fluctuations and very high peak levels in untreated patients; standard treatment with two or three daily doses of corticosteroids did not prevent a pronounced rise in its level after midnight. After the first morning dose of hydrocortisone a very steep fall was observed. The 24-hour pregnanetriol excretion correlated well with the corresponding total integrated 1 7-hydroxyprogesterone area. It is concluded that single 1 7-hydroxyprogesterone values are unlikely to give adequate information about the quality of treatment.
In patients with congenital adrenal hyperplasia control of glucocorticoid substitution therapy is governed by clinical parameters (growth velocity, bone age, pubertal stage) together with biochemical data on 17-ketosteroids (17-KS) and pregnanetriol. Recent advances have drawn attention to the plasma levels of cortisol precursors, especially of 17-hydroxyprogesterone (17-OHP),1 the value of monitoring this steroid in the management of congenital adrenal hyperplasia having been investigated2-9 and found to be limited by the well-known circadian rhythm.'0 The effect of the time lag between ingesting the drug and blood sampling has not been fully studied, and the same applies to the circadian rhythm. Information on plasma levels of cortisol under substitution therapy is also lacking. Therefore we have studied the circadian patterns of cortisol, 1 7-OHP, and testosterone under glucocorticoid therapy, and in addition, using the urinary parameters of 17-KS and pregnanetriol, we have assessed the usefulness of single 17-OHP values in the monitoring of treatment.
Patients and methods
In 9 girls and 2 boys aged between 2j and 16j years under treatment for congenital adrenal hyperplasia due to 21-hydroxylase-deficiency, blood was drawn at 90-minute intervals during a 24-hour period to determine the levels of 17-OHP, cortisol, and testosterone. Levels of 17-KS and pregnanetriol were measured in the corresponding 24-hour urine samples. Three patients (Cases 8, 10, 11) were also studied after stopping treatment for 3 days; one newly diagnosed boy (Case 9) was studied before treatment began and then 2 weeks later. Informed consent for the investigation was obtained from the parents.
Clinical data are shown in Table 1 . Glucocorticoids (hydrocortisone or prednisone) were given three times daily at 0800, 1230, and 1830 hours, or twice at 0800 and 1830. Seven patients were treated with hydrocortisone in a mean dose of 19 1 mg/M2, and 4 patients received prednisone in a mean dose of 8 8 mg/M2. Two girls (Cases 2 and 6) were given larger prednisone doses but only temporarily.
Details of the methods used are shown in Table 2 . Antisera against 1 7-hydroxyprogesterone-3-oxime-BSA and cortisol-21-succinate-BSA were supplied by Endocrine Sciences, antiserum against testosterone-3-oxime-BSA by New England Nuclear. Crossreaction of cortisol antibody with prednisone was 208 9 ml discard 9 ml (hydrocortisone) dry down, redissolve in 1 ml ethanol, take 1/10 for recovery and suitable aliquots for radioimmunoassay nearly complete; in patients being treated with prednisone therefore, the data for cortisol represent the sum of drug and endogenous cortisol. Levels of 17-KS were determined spectrophotometrically, and those of pregnanetriol by gas chromatography, using standard laboratory methods. 1 shows the diurnal variation of plasma cortisol (or sum of prednisone and cortisol) in children without and with treatment. After glucocorticoid intake there was a rapid rise of plasma levels, the peak values (sometimes unphysiologically high) clearly reflecting the dose. Fall-off was very steep too, especially with hydrocortisone, and after midnight very low levels persisted. In children not on treatment, a weak circadian rhythm still existed. In one girl (Case 10) we found cortisol fluctuation almost normal after the drug had been stopped for 3 days. Fig. 2 shows the corresponding 17-OHP values. Pronounced fluctuations, extremely high morning and relatively low evening values, characterise the condition without (or before) treatment. Generally, high morning levels were rapidly reduced by the first dose (at 0800 hours). They remained fairly low throughout the day irrespective of the mode of drug application. A steep rise occurred generally during the night between 2300 and 0330 hours. This rise took place later in patients who were given a larger hydrocortisone dose in the evening, and in patients being treated with predisone. Only in the 2 patients who received an increased predisone dose for clinical reasons were the 17-OHP levels low throughout the entire 24-hour period.
The circadian pattern of plasma testosterone is shown in Fig. 3 . Considerable fluctuations were noted, especially in untreated patients. Under glucocorticoid treatment the daytime levels were low, and a rapid increase was seen after midnight or earlier, with peak values in the morning.
In Table 3 the 24-hour integrated 17-OHP areas are summarised, the relative fractions of integrated 17-OHP areas for two 12-hour periods (1200-2400 and 2400-1200), integrated testosterone areas, and the corresponding urinary values of 17-KS and pregnanetriol are shown. The integrated areas represent the area between abscissa and the respective steroid curves as shown in the corresponding figures. Correlation between the 24-hour integrated 17-OHP areas and the urinary pregnanetriol (r = 0-79, P<0-01) was good. In order to demonstrate the difference in suppression at different periods of the day, the total integrated area was divided into two 12-hour periods-that is 1200-2400 and 2400-1200. Under such conditions the 1200-2400 period was much lower than the 2400-1200 period, and there was no correlation in either period with pregnanetriol (r = 0-22 and r = 0 37 respectively). This observation was made in all treated patients except the 2 children with very high prednisone doses.
Integrated well-suppressed (day) and insufficiently-suppressed (night) periods, we divided the total integrated Circadian patterns ofplasma cortisol 213 and 6) the 17-OHP integrated area of the first period was distinctly smaller, and correlations between either fraction and urinary pregnanetriol were no longer significant. Hence, we question whether the 24-hour urinary pregnanetriol excretion which represented a mean of very unequal plasma 17-OHP periods, gave adequate information about the quality of corticosteroid therapy.
In conclusion, a single 17-OHP value is not a useful parameter for monitoring treatment in congenital adrenal hyperplasia; while standardisation of sampling time is not possible owing to the rapid changes in 1 7-OHP levels during the day.
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